DDInter899 DDInter1026
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved
Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and Trk activation, which results in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress Trk. Larotrectinib was granted accelerated approval by the FDA in November 2018 for the treatment of Trk-positive solid tumors. It was notable for being the second tissue-agnostic chemotherapy ever approved by the FDA.
Larotrectinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sibutramine
Larotrectinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lefamulin
Larotrectinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Calaspargase pegol
Larotrectinib {u} may lead to a major life threatening interaction when taken with {v} Pimozide
Larotrectinib may cause a minor interaction that can limit clinical effects when taken with Sibutramine
Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Larotrectinib may lead to a major life threatening interaction when taken with Pimozide